WO2005041873A3 - Formulation of exendin-4 - Google Patents

Formulation of exendin-4 Download PDF

Info

Publication number
WO2005041873A3
WO2005041873A3 PCT/US2004/035088 US2004035088W WO2005041873A3 WO 2005041873 A3 WO2005041873 A3 WO 2005041873A3 US 2004035088 W US2004035088 W US 2004035088W WO 2005041873 A3 WO2005041873 A3 WO 2005041873A3
Authority
WO
WIPO (PCT)
Prior art keywords
exendin
articles
methods
formulation
articles made
Prior art date
Application number
PCT/US2004/035088
Other languages
French (fr)
Other versions
WO2005041873A2 (en
Inventor
Stephen C Rowe
Durga Annavajjula
Original Assignee
Azopax Therapeutics Llc
Stephen C Rowe
Durga Annavajjula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azopax Therapeutics Llc, Stephen C Rowe, Durga Annavajjula filed Critical Azopax Therapeutics Llc
Publication of WO2005041873A2 publication Critical patent/WO2005041873A2/en
Publication of WO2005041873A3 publication Critical patent/WO2005041873A3/en
Priority to US11/410,269 priority Critical patent/US20070053954A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods and articles for the administration of exendin-4. These methods and articles provide for the controlled and sustained delivery of relatively large quantities of exendin-4 with a low burst effect. The articles made using the method of the invention have increased percentages (w/w) of macromer, increased crosslinking density, and reduced pore size in comparison to articles made using solution methods.
PCT/US2004/035088 2003-10-24 2004-10-25 Formulation of exendin-4 WO2005041873A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/410,269 US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51424303P 2003-10-24 2003-10-24
US60/514,243 2003-10-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/410,269 Continuation-In-Part US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Publications (2)

Publication Number Publication Date
WO2005041873A2 WO2005041873A2 (en) 2005-05-12
WO2005041873A3 true WO2005041873A3 (en) 2005-07-21

Family

ID=34549321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035088 WO2005041873A2 (en) 2003-10-24 2004-10-25 Formulation of exendin-4

Country Status (1)

Country Link
WO (1) WO2005041873A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062652B2 (en) 2004-06-17 2011-11-22 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating precocious puberty
AU2006223161B2 (en) 2005-03-11 2011-05-12 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
MX2008002370A (en) * 2005-08-19 2008-04-29 Amylin Pharmaceuticals Inc Exendin for treating diabetes and reducing body weight.
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
NZ580803A (en) 2007-04-27 2012-03-30 Endo Pharmaceuticals Solutions Implant device release agents and methods of using same
WO2009040085A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s)
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
JP5536053B2 (en) 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． Octreotide implant with release agent
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
WO2005041873A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
WO2004084950A3 (en) Cell targeting methods and compositions
WO2004091446A3 (en) Medical device delivery systems
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
AU2003273259A1 (en) Drug cartridge assembly and method of manufacture
WO2006055603A3 (en) Injectable nanoparticulate olanzapine formulations
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2006030402A3 (en) Dual compartment osmotic delivery device
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
AU2003234336A1 (en) Methods and compositions for use in preparing sirnas
MX2007002189A (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery.
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2003028660A3 (en) Drug delivery devices and methods
WO2006101882A3 (en) Medicament delivery formulations, devices and methods
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
WO2005012243A3 (en) Substituted indole-o-glucosides
AU2003287726A1 (en) Intraocular delivery compositions and methods
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
WO2006079928A3 (en) Polyelectrolyte multilayer film, preparation and uses thereof
WO2005041873A3 (en) Formulation of exendin-4
AU2002254942A1 (en) Paracetamol solutions which are stable in storage and ready for infusion
WO2005039502A3 (en) Macromer-melt formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11410269

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11410269

Country of ref document: US